Zelira Therapeutics (ASX:ZLD) YoY EPS Growth: 51.01% (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Zelira Therapeutics YoY EPS Growth?

Zelira Therapeutics ASX:ZLD YoY EPS Growth is 51.01% as of Jun. 2025. The stock has 7 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Zelira Therapeutics's YoY EPS Growth for the quarter that ended in Jun. 2025 was 51.01%.

Zelira Therapeutics's Earnings per Share (Diluted) for the six months ended in Jun. 2025 was A$-0.10.

Zelira Therapeutics YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Zelira Therapeutics's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zelira Therapeutics YoY EPS Growth Chart

Zelira Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.04 -20.81 64.12 -481.77 90.20

Zelira Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 71.41 -784.50 6.16 92.76 51.01

Zelira Therapeutics YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Zelira Therapeutics's YoY EPS Growth for the fiscal year that ended in Jun. 2025 is calculated as:

YoY EPS Growth (A: Jun. 2025 )
=(Earnings per Share (Diluted) (A: Jun. 2025 )-Earnings per Share (Diluted) (A: Jun. 2024 ))/ | Earnings per Share (Diluted) (A: Jun. 2024 ) |
=(-0.316--3.223)/ | -3.223 |
=90.20 %

Zelira Therapeutics's YoY EPS Growth for the quarter that ended in Jun. 2025 is calculated as:

YoY EPS Growth (Q: Jun. 2025 )
=(Earnings per Share (Diluted) (Q: Jun. 2025 )-Earnings per Share (Diluted) (Q: Jun. 2024 )) / | Earnings per Share (Diluted) (Q: Jun. 2024 )) |
=(-0.097--0.198)/ | -0.198 |
=51.01 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 51.01% mean?
Zelira Therapeutics (ASX:ZLD) has a YoY EPS Growth of 51.01% as of Jun. 2025. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Zelira Therapeutics and its competitors.
Is Zelira Therapeutics' YoY EPS Growth too high?
Zelira Therapeutics' current YoY EPS Growth is 51.01%.
How does Zelira Therapeutics' YoY EPS Growth compare to CLDI and CRIS?
Zelira Therapeutics' YoY EPS Growth of 51.01% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Biotechnology company?
A good YoY EPS Growth depends on the Biotechnology industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Zelira Therapeutics and its competitors. Zelira Therapeutics's current YoY EPS Growth is 51.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelira Therapeutics stock overvalued right now?
Zelira Therapeutics (ASX:ZLD) has a current YoY EPS Growth of 51.01%. The stock's GF Value™ is A$0.12, compared to a current price of A$0.50 — trading 316.7% above its estimated fair value. The current YoY EPS Growth is 51.01%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Zelira Therapeutics (ASX:ZLD), the current YoY EPS Growth is 51.01% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zelira Therapeutics Business Description

Other Exchanges ZLDAF:USA
Address 101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.